Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: A systematic review of the literature

Rheumatology (United Kingdom)

Volumn 54, Issue 5, 2014, Pages 915-926

  Behrens, Frank ^a   Cañete, Juan D ^b   Olivieri, Ignazio ^c,d   Van Kuijk, Arno W ^e   McHugh, Neil ^f   Combe, Bernard ^g  

^a GOETHE UNIVERSITY   (Germany)

^b HOSPITAL CLÍNIC   (Spain)

^c SAN CARLO HOSPITAL   (Italy)

^d Potenza/Madonna delle Grazie Hosp   (Italy)

^e Jan Van Breemen Research Institute/Reade   (Netherlands)

^f ROYAL NATIONAL HOSPITAL FOR RHEUMATIC DISEASES   (United Kingdom)

^g UNIV MONTPELLIER   (France)

Author keywords

Adalimumab; Certolizumab pegol; Etanercept; Golimumab; Infliximab; Methotrexate; Psoriatic arthritis; TNF inhibitors

Indexed keywords

METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; HUMAN; IMMUNOGENICITY; MONOTHERAPY; MULTICENTER STUDY (TOPIC); POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84929669085     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu415     Document Type: Article

References (45)

1. Ash Z, Gaujoux-Viala C, Gossec L et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012;71:319-26.
2. Saber TP, Ng CT, Renard G et al. Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther 2010;12:R94.
3. Gossec L, Smolen JS, Gaujoux-Viala C et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4-12.
4. Ritchlin CT, Kavanaugh A, Gladman DD et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387-94.
5. Smolen JS, Landewé R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
6. Gottlieb AB, Langley RG, Strober BE et al. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol 2012; 167:649-57.
7. Zachariae C, Mørk NJ, Reunala T et al. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol 2008;88:495-501.
8. van den Reek JM, van Lümig PP, Kievit W et al. Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice. J Dermatolog Treat 2013;24:361-8.
9. Antoniou C, Stefanaki I, Stratigos A et al. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre. Br J Dermatol 2010;162:1117-23.
10. Wee JS, Petrof G, Jackson K, Barker JN, Smith CH. Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre. Br J Dermatol 2012;167:411-16.
11. Adişen E, Aral A, Aybay C, Gürer MA. Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: a pilot study. J Dermatol 2010;37:708-13.
12. van Kuijk AW, de Groot M, Stapel SO et al. Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis 2010;69:624-5.
13. Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis 2012;71:1914-5.
14. Plasencia C, Pascual-Salcedo D, Nuño L et al. Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab. Ann Rheum Dis 2012;71:1955-60.
15. Zisapel MZ, Madar-Balakirsi N, Padova H et al. Immunogenicity of TNFa blockers in patients with psoriatic arthritis [abstract]. Arthritis Rheum 2013;65(Suppl 10):S1062.
16. Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89.
17. Gladman DD, Mease PJ, Ritchlin CT et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007;56:476-88.
18. Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72.
19. Sterry W, Ortonne JP, Kirkham B et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010;340:c147.
20. Combe B, Kerkmann U, Brock F, Gallo G. Response to etanercept with or without methotrexate combination therapy in patients with psoriatic arthritis [abstract]. Arthritis Rheum 2013;65(Suppl 10):S154.
21. Kavanaugh A, McInnes I, Mease P et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86.
22. Kavanaugh A, McInnes IB, Mease PJ et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis 2013;72:1777-85.
23. Kavanaugh A, van der Heijde D, McInnes IB et al. 5 Year safety, efficacy, and radiographic data in patients with active psoriatic arthritis treated with golimumab:results from the long-term extension of a randomized, placebo-controlled study [abstract]. Arthritis Rheum 2012;64(Suppl 10):S938.
24. Kavanaugh A, van der Heijde D, McInnes IB et al. 5 Year safety, efficacy, and radiographic data in patients with active psoriatic arthritis treated with golimumab: long-term extension results of the randomized, placebo-controlled study GO-REVEAL [abstract]. Ann Rheum Dis 2013; 72(Suppl 3):674.
25. Antoni CE, Kavanaugh A, Kirkham B et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52:1227-36.
26. Antoni C, Krueger GG, de Vlam K et al. IMPACT 2 Trial Investigators: Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7.
27. Kavanaugh A, Antoni C, Krueger GG et al. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis 2006;65:471-7.
28. Kavanaugh A, Krueger GG, Beutler A et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment:results from the IMPACT 2 trial. Ann Rheum Dis 2007;66:498-505.
29. van der Heijde D, Kavanaugh A, Gladman DD et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007;56:2698-707.
30. Mease PJ, Fleischmann R, Deodhar AA et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014;73:48-55.
31. Heiberg MS, Koldingsnes W, Mikkelsen K et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008;59:234-40.
32. Fagerli KM, Lie E, van der Heijde D et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 2014; 73:132-7.
33. Kristensen LE, Gülfe A, Saxne T, Geborek P. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 2008; 67:364-9.
34. Saad AA, Ashcroft DM, Watson KD et al. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology 2010;49:697-705.
35. Virkki LM, Sumathikutty BC, Aarnio M et al. Biological therapy for psoriatic arthritis in clinical practice: outcomes up to 2 years. J Rheumatol 2010;37:2362-8.
36. Glintborg B, Østergaard M, Dreyer L et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor a therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011;63:382-90.
37. Hoa S, Choquette D, Bessette L et al. Comparing adalimumab and etanercept as first line agents in patients with psoriatic arthritis: data from the Rhumadata_ clinical database and registry [abstract]. Arthritis Rheum 2013; 65(Suppl 10):S145.
38. Heiberg MS, Kaufmann C, Rødevand E et al. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. Ann Rheum Dis 2007;66:1038-42.
39. Saad AA, Ashcroft DM, Watson KD et al. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 2009;11:R52.
40. Mease P, Collier D, Saunders K et al. Biologic therapy, time to low disease activity, and effect of mono vs. background oral DMARD therapy among psoriatic arthritis patients in a US registry [abstract]. Ann Rheum Dis 2013; 72(Suppl 3):671.
41. Eder L, Chandran V, Schentag CT et al. Time and predictors of response to tumour necrosis factor-alpha blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort. Rheumatology 2010;49:1361-6.
42. Scarpa R, Atteno M, Lubrano E et al. The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study. Clin Rheumatol 2011;30:1063-7.
43. Spadaro A, Ceccarelli F, Scrivo R, Valesini G. Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis. Ann Rheum Dis 2008;67:1650-1.
44. Kingsley GH, Kowalczyk A, Taylor H et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology 2012;51:1368-77.
45. Bonafede M, Johnson BH, Fox KM, Watson C, Gandra SR. Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting. J Dermatol Treat 2013;24:369-73.